BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates ...

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product ...

(RTTNews) - Zivo Bioscience Inc. (ZIVO) announced negative results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial ...

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product ...

Expects to enter into formal negotiations with a global animal health company in January 2025 and to finalize an agreement in the first quarter of 2025 BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo ...

As the result of research in Great Britain and in the United States, the use of certain sulphonamides, particularly sulphamezathine, has become the standard method of treatment of acute cæcal ...

This is a preview. Log in through your library . Abstract Three trials were conducted to study the effects of Eimeria necatrix infection upon young chickens. Four-week-old chicks were inoculated with ...

IN a previous communication 1, two experiments were described in which mepacrine hydrochloride appeared to have a beneficial effect in the treatment of acute cæcal coccidiosis of chicks. In two ...